Regenxbio Valuation
| RGNX Stock | USD 8.16 0.53 6.10% |
At this time, the company appears to be undervalued. Regenxbio holds a recent Real Value of $14.2 per share. The prevailing price of the company is $8.16. Our model determines the value of Regenxbio from analyzing the company fundamentals such as Return On Equity of -0.47, operating margin of 0.14 %, and Shares Outstanding of 50.39 M as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Regenxbio's price fluctuation is slightly risky at this time. Calculation of the real value of Regenxbio is based on 3 months time horizon. Increasing Regenxbio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Regenxbio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Regenxbio Stock. However, Regenxbio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 8.16 | Real 14.2 | Hype 8.79 | Naive 8.47 |
The intrinsic value of Regenxbio's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Regenxbio's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Regenxbio helps investors to forecast how Regenxbio stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Regenxbio more accurately as focusing exclusively on Regenxbio's fundamentals will not take into account other important factors: Regenxbio Total Value Analysis
Regenxbio is at this time estimated to have valuation of 223.15 M with market capitalization of 411.17 M, debt of 82.03 M, and cash on hands of 402.96 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Regenxbio fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
223.15 M | 411.17 M | 82.03 M | 402.96 M |
Regenxbio Investor Information
About 88.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.5. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Regenxbio has Price/Earnings To Growth (PEG) ratio of 0.26. The entity recorded a loss per share of 3.09. The firm had not issued any dividends in recent years. Based on the analysis of Regenxbio's profitability, liquidity, and operating efficiency, Regenxbio is not in a good financial situation at this time. It has a very high odds of going through financial crisis in August.Regenxbio Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Regenxbio has an asset utilization ratio of 17.88 percent. This suggests that the Company is making $0.18 for each dollar of assets. An increasing asset utilization means that Regenxbio is more efficient with each dollar of assets it utilizes for everyday operations.Regenxbio Ownership Allocation
Regenxbio owns a total of 50.39 Million outstanding shares. The majority of Regenxbio outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Regenxbio to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Regenxbio. Please pay attention to any change in the institutional holdings of Regenxbio as this could imply that something significant has changed or is about to change at the company. On November 14, 2019, Representative Peter Welch of US Congress acquired under $15k worth of Regenxbio's common stock.Regenxbio Profitability Analysis
The company reported the previous year's revenue of 83.33 M. Net Loss for the year was (227.1 M) with profit before overhead, payroll, taxes, and interest of 125.75 M.About Regenxbio Valuation
Our relative valuation model uses a comparative analysis of Regenxbio. We calculate exposure to Regenxbio's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Regenxbio's related companies.REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland. Regenxbio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 372 people.
Regenxbio Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 49.5 M |
Additional Tools for Regenxbio Stock Analysis
When running Regenxbio's price analysis, check to measure Regenxbio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regenxbio is operating at the current time. Most of Regenxbio's value examination focuses on studying past and present price action to predict the probability of Regenxbio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regenxbio's price. Additionally, you may evaluate how the addition of Regenxbio to your portfolios can decrease your overall portfolio volatility.